TrioxBio Israeli Company

TrioxBio develops and commercializes proprietary synthetic small molecules to treat pathologic states caused by the overproduction of nitric oxide. The company's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a nitric oxide synthase (NOS) inhibitor that blocks the production of nitric oxide, preventing the dilation of blood vessels and other detrimental effects caused by excessive NOS activity.

Health Tech & Life Sciences Biotechnology Health Care Medical

Alternatives

No alternatives listed yet.

Suggest an Alternative

Name *

URL *

Founders

Shlomo Sadoun

Office Locations

Ramat Gan, Israel

References

[1]

techaviv.com - https://www.techaviv.com/people/roy-farfara-md

[2]

finder.startupnationcentral.org - https://finder.startupnationcentral.org/company_page/trioxbio

[3]

crunchbase.com - https://www.crunchbase.com/organization/trioxbio-inc

External links are provided for reference and verification purposes.